Literature DB >> 1768613

Effects of ancrod and rtPA on fibrin accumulation, glomerular inflammation and renal function in nephrotoxic nephritis.

P W Mathieson1, S Thiru, D K Peters, D B Oliveira.   

Abstract

We have compared the effects of ancrod and recombinant tissue plasminogen activator (rtPA) on nephrotoxic nephritis induced in pre-immunized rabbits by the administration of nephrotoxic globulin (NTG; sheep anti-rabbit glomerular basement membrane). We used three different doses of NTG: in each experiment three groups of six rabbits were preimmunized with normal sheep globulin and given NTG: group A received no further treatment; group B received rtPA, 2 mg/kg 12 hourly; group C received ancrod 2 U/kg 12 hourly. Animals were bled daily for estimation of plasma fibrinogen and serum creatinine, then killed on day 5 and kidneys removed for histology. 1 ml/kg of NTG caused massive glomerular necrosis, all three groups having severe renal failure. With 0.5 ml/kg of NTG, ancrod and rtPA both effectively prevented fibrin deposition in Bowman's space, but all animals had severe proliferative glomerulonephritis and marked renal failure. With 0.25 ml/kg of NTG, control animals developed severe proliferative nephritis and advanced renal failure, ancrod provided almost complete protection, and the rtPA group had renal injury and functional impairment intermediate between the other two groups. We conclude that renal failure in severe nephrotoxic nephritis is fibrin-independent, but in less fulminant nephritis renal function can be protected by defibrination with ancrod. rtPA is capable of reducing glomerular fibrin accumulation as effectively as ancrod, but provides inferior protection of renal function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1768613      PMCID: PMC2002439     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  13 in total

1.  THE PATHOGENIC ROLE OF THE COAGULATION PROCESS IN RABBIT MASUGI NEPHRITIS.

Authors:  P VASSALLI; R T MCCLUSKEY
Journal:  Am J Pathol       Date:  1964-10       Impact factor: 4.307

2.  Effects of heparin on experimental nephritis in rabbits.

Authors:  J KLEINERMAN
Journal:  Lab Invest       Date:  1954 Nov-Dec       Impact factor: 5.662

3.  A quantitative evaluation of anticoagulants in experimental nephrotoxic nephritis.

Authors:  N M Thomson; I J Simpson; D K Peters
Journal:  Clin Exp Immunol       Date:  1975-02       Impact factor: 4.330

4.  Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.

Authors:  S Kim; N K Wadhwa; K S Kant; V E Pollak; P Glas-Greenwalt; M A Weiss; C G Hong
Journal:  Q J Med       Date:  1988-11

5.  Blood coagulation and the effect of warfarin treatment on renal disease in NZB-NZW mice.

Authors:  A R McGiven
Journal:  Br J Exp Pathol       Date:  1967-10

Review 6.  Immunopathogenesis of crescentic glomerulonephritis and lung purpura.

Authors:  D J Salant
Journal:  Kidney Int       Date:  1987-09       Impact factor: 10.612

7.  The effects of defibrination with ancrod in experimental allergic glomerular injury.

Authors:  P F Naish; D J Evans; D K Peters
Journal:  Clin Exp Immunol       Date:  1975-05       Impact factor: 4.330

8.  Fibrinolytic therapy with streptokinase for established experimental glomerulonephritis.

Authors:  P G Tipping; S R Holdsworth
Journal:  Nephron       Date:  1986       Impact factor: 2.847

9.  Defibrination with ancrod in glomerulonephritis: effects on clinical and histologic findings and on blood coagulation.

Authors:  V E Pollak; H I Glueck; M A Weiss; A Lebron-Berges; M A Miller
Journal:  Am J Nephrol       Date:  1982       Impact factor: 3.754

10.  Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction.

Authors:  J M Bergstein
Journal:  Kidney Int       Date:  1989-01       Impact factor: 10.612

View more
  1 in total

1.  Fibrinogen mediates platelet-polymorphonuclear leukocyte cooperation during immune-complex glomerulonephritis in rats.

Authors:  X Wu; M H Helfrich; M A Horton; L P Feigen; J B Lefkowith
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.